Also trades as: 0VQA.L (LSE) · $vol 0M
VKTX NASDAQ
Viking Therapeutics, Inc.
1W: -6.8%
1M: -24.6%
3M: -25.5%
YTD: -29.7%
1Y: -27.7%
3Y: +148.3%
5Y: +326.4%
$24.89
+0.68 (+2.81%)
Pre-Market: $25.09 (+0.20, +0.80%)
Weekly Expected Move ±9.4%
$20
$22
$24
$27
$29
Credit Risk of going bust: lower than 84% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Viking Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.1M against a stock market value of $3.17B.
Distance to default 10.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 66.3%; Altman Z'' -5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Viking Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.1M against a stock market value of $3.17B.
Distance to default 10.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 66.3%; Altman Z'' -5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.13
Neutral
1 bullish
4 neutral
2 bearish
Articles (7d)
7
Daily Sentiment (7 Days)
Articles (100)
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics Starts Phase III Development of Obesity Pill
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
4 High-Risk Stocks Built for Big Returns
3 Absurdly Cheap Stocks to Buy Before the End of 2026
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.
2 Stocks That Could Soar in Q4
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
VKTX Advances Obesity Program With New Oral Maintenance Study
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Here Are My Top 4 Stocks to Buy in October
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
Prediction: This Stock Could Double Over the Next 5 Years
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
3 Non-AI Growth Stocks That Have Massive Upside
Viking Therapeutics nets ~$550M in proceeds from latest offering
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
Viking Therapeutics, Inc. $VKTX Shares Newly Acquired by Bank of America Corp DE
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Here's Why Viking Therapeutics Shares Slumped Today
Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes
At a glance: stocks gapping down premarket
Biggest stock movers Thursday: P, VKTX, MGM, and more
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Viking Therapeutics files plans for $400M in combined offerings of common stock, convertible notes
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Why Viking Therapeutics Stock Skyrocketed on Tuesday
Viking Thera adds most since 2024 after “clean” safety data for obesity drug
Biggest stock movers Tuesday: VKTX, GME, VICR, and more
Viking Therapeutics soars after trial data for obesity drug
4 Biotech Stocks to Watch as Potential Takeover Targets
Baird Financial Group Inc. Makes New Investment in Viking Therapeutics, Inc. $VKTX
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
Baron Global Opportunity Fund adds GOOG, CBRS; exits PDD, WIX
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Jupiter Topco LLC Makes New Investment in Viking Therapeutics, Inc. $VKTX
AXQ Capital LP Buys 56,796 Shares of Viking Therapeutics, Inc. $VKTX
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Canada Pension Plan Investment Board Makes New Investment in Viking Therapeutics, Inc. $VKTX
Bank of New York Mellon Corp Takes Position in Viking Therapeutics, Inc. $VKTX
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
2 GLP-1 Stocks That Could Double Your Money by 2031
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?